Last updated: April 2, 2024
Sponsor: Pell Bio-Med Technology Co., Ltd.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Lymphoma, B-cell
Follicular Lymphoma
Lymphoma
Treatment
Pell's lentiviral-based gene-edited immune cell therapy
Clinical Study ID
NCT05377307
PLLV-LTFU-401
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients must have ever received Pell's lentiviral-based gene-edited immune cell asmonotherapy or as combination therapy in clinical trials.
- The last lentiviral-based gene-edited immune cell infusion within 15 years.
- Patient/patient's parent/legal guardian is capable of giving signed informed consentwhich includes compliance with the requirements and restrictions listed in theinformed consent form (ICF) and in this protocol.
Exclusion
Exclusion Criteria: There are no specific exclusion criteria for this study.
Study Design
Total Participants: 49
Treatment Group(s): 1
Primary Treatment: Pell's lentiviral-based gene-edited immune cell therapy
Phase:
Study Start date:
December 29, 2022
Estimated Completion Date:
December 31, 2037
Study Description
Connect with a study center
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, 807377
TaiwanActive - Recruiting
National Taiwan University Hospital
Taipei, 10025
TaiwanActive - Recruiting
Taipei Veterans General Hospital
Taipei, 112201
TaiwanSite Not Available
Taipei Medical University - Taipei Medical University Hospital
Taipei city, 11031
TaiwanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.